Philadelphia gene therapy company Passage Bio names former Novartis executive as new CEO
Philadelphia gene therapy company Passage Bio appointed Dr. Will Chou, former Novartis executive, as its new CEO.
Penn Spinout and I-Corps Participant Innervace Raises $40 Million for Parkinson’s Disease Research
The funds will allow Innervace to advance their platform and lead asset in Parkinson’s disease, which aims to reconstruct the neuronal circuitry that is lost in Parkinson's patients.
The Power of Pennovation Works: Research and Development
In November, in recognition of the 5th year anniversary of Pennovation Works, the Pennovation Center hosted The Power of Pennovation Works: Research and Development panel.
Philadelphia Ranks Second in New Study Comparing U.S. Cell and Gene Therapy Hubs
Philadelphia ranks second in a newly released study comparing 14 U.S. cell and gene therapy hubs in five key categories.
Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.
Weissman Lab is Working on New Type of Vaccines to Protect Against All Coronaviruses
The Weissman Lab is working towards developing vaccines that not only target multiple COVID variants, but also multiple types of coronaviruses.
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
The combined company, which is expected to operate under the name Carisma Therapeutics Inc., will focus on advancing Carisma’s proprietary cell therapy platform.
Five Philadelphia Organizations Are Partnering for a New Biotech Technician Training Program Starting this Fall
Five organizations will partner for a paid workforce development training program called Biomedical Technician Training Program: Aseptic Manufacturing.
Penn spinout Capstan Therapeutics Launches with Goal of Incorporating mRNA into CAR-T Cell Therapy
This new approach to CAR-T therapy will involve mRNA therapy that directs cells in the body to make proteins to prevent or fight disease.